TBIO - トランスジェノミック (Translate Bio Inc.) トランスジェノミック

 TBIOのチャート


 TBIOの企業情報

symbol TBIO
会社名 Transgenomic Inc (トランスジェノミック)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Translate Bio Inc. is a messenger RNA or mRNA therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform or MRT platform and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung MRT5005 is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.   トランスジェノミックは米国のバイオ企業。コネチカットとネブラスカ州の臨床検査室で心臓、神経、ミトコンドリア異常、がん疾患の遺伝子検査を行う。また、分子遺伝学研究と分子診断用の遺伝子解析システム「ウェ―ブ」を製造、販売するほか、他社の生体計測装置を販売。また、機器の据え付け、保守、技術サポ―トを提供。   Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.
本社所在地 12325 Emmet Street Omaha NE 68164 USA
代表者氏名
代表者役職名
電話番号 +1 617-945-7361
設立年月日 35490
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数 37人
url www.transgenomic.com
nasdaq_url https://www.nasdaq.com/symbol/tbio
adr_tso
EBITDA EBITDA(百万ドル) -94.58100
終値(lastsale) 8.8799
時価総額(marketcap) 400853693.031
時価総額 時価総額(百万ドル) 347.59100
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 523.63600
当期純利益 当期純利益(百万ドル) -89.80400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Translate Bio Inc revenues was not reported. Net loss applicable to common stockholders increased 52% to $48.1M. Higher net loss reflects Change in fair value of contingent consi increase from $4.6M to $12.8M (expense) General and Administrative - Balancing increase of 51% to $9M (expense) Research and development - Balancing increase of 13% to $25.5M (expense).

 TBIOのテクニカル分析


 TBIOのニュース

   Translate Bio gets $50M mRNA vaccine program milestone payment from Sanofi Pasteur  2021/06/07 11:58:34 Seeking Alpha
   Translate Bio Inc (TBIO) falls 2.22% for May 19  2021/05/19 22:00:02 Equities
Translate Bio Inc (NASDAQ: TBIO) shares fell -2.22% to end trading Wednesday at $17.19 per share - a net change of $-0.39. Shares traded between $17.45 and $16.87 throughout the day. 435896 shares of Translate Bio Inc exchanged hands. Visit Translate Bio Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Translate Bio Inc and to follow the companys latest updates, you can visit the companys profile page here: Translate Bio Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Translate Bio''s mRNA Therapeutic For Respiratory Tract Infections Shows Promise In Animal Studies  2021/05/18 18:40:59 Benzinga
Translate Bio Inc (NASDAQ: TBIO ) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease. The data were presented at Full story available on Benzinga.com
   Translate Bio (TBIO) Investor Presentation - Slideshow  2021/05/17 18:51:34 Seeking Alpha
   Translate Bio Inc. Shares Close the Week 33.1% Lower - Weekly Wrap  2021/03/19 22:30:00 Kwhen Finance
Translate Bio Inc. shares closed this week 33.1% lower than it did at the end of last week. The stock is currently down 10.7% year-to-date, up 68.4% over the past 12 months, and up 507.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.8%. Trading Activity Shares traded as high as $26.30 and as low as $16.38 this week.Shares closed 5e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 220.5% higher than the 10-day average and 466.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -225.1% The company's stock price performance over the past 12 months lags the peer average by -30.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Translate Bio gets $50M mRNA vaccine program milestone payment from Sanofi Pasteur  2021/06/07 11:58:34 Seeking Alpha
   Translate Bio Inc (TBIO) falls 2.22% for May 19  2021/05/19 22:00:02 Equities
Translate Bio Inc (NASDAQ: TBIO) shares fell -2.22% to end trading Wednesday at $17.19 per share - a net change of $-0.39. Shares traded between $17.45 and $16.87 throughout the day. 435896 shares of Translate Bio Inc exchanged hands. Visit Translate Bio Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Translate Bio Inc and to follow the companys latest updates, you can visit the companys profile page here: Translate Bio Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Translate Bio''s mRNA Therapeutic For Respiratory Tract Infections Shows Promise In Animal Studies  2021/05/18 18:40:59 Benzinga
Translate Bio Inc (NASDAQ: TBIO ) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease. The data were presented at Full story available on Benzinga.com
   Translate Bio (TBIO) Investor Presentation - Slideshow  2021/05/17 18:51:34 Seeking Alpha
   Translate Bio Inc. Shares Close the Week 33.1% Lower - Weekly Wrap  2021/03/19 22:30:00 Kwhen Finance
Translate Bio Inc. shares closed this week 33.1% lower than it did at the end of last week. The stock is currently down 10.7% year-to-date, up 68.4% over the past 12 months, and up 507.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.8%. Trading Activity Shares traded as high as $26.30 and as low as $16.38 this week.Shares closed 5e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 220.5% higher than the 10-day average and 466.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -225.1% The company's stock price performance over the past 12 months lags the peer average by -30.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Translate Bio's mRNA Therapeutic For Respiratory Tract Infections Shows Promise In Animal Studies  2021/05/18 18:40:59 Benzinga
Translate Bio Inc (NASDAQ: TBIO ) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease. The data were presented at … Full story available on Benzinga.com
   Leerink Partners Stick to Their Hold Rating for Translate Bio Inc By Investing.com  2021/05/10 12:27:28 Investing.com
Leerink Partners Stick to Their Hold Rating for Translate Bio Inc
   Evercore ISI Stick to Their Hold Rating for Translate Bio Inc By Investing.com  2021/05/09 10:10:30 Investing.com
Evercore ISI Stick to Their Hold Rating for Translate Bio Inc
   Translate Bio Inc $TBIO: Cash per share is equal to $4.67, and the stock price is $17.525!  2021/03/18 15:26:51 StockMarketRevolution
With 73 million shares outstanding, at $17.525 per share, the market capitalization of Translate Bio Inc (TBIO) is equal to
   Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies  2020/08/25 19:13:53 Reuters
Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.

 関連キーワード  (医薬品 米国株 トランスジェノミック TBIO Translate Bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)